{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218745","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.561265+00:00","generated_at":"2026-06-24T00:54:03.083225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amylyx Q2 net loss $54.1M ($0.93/shr); ALBRIOZA launched in Canada; FDA PDUFA Sept 29","bullets":["Net loss $54.1M vs $21.9M in Q2 2021; R&D $24.3M, G&A $30.0M; no product revenue.","Cash & equivalents $206.7M at June 30, down from $255.2M at March 31, 2022.","ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022.","FDA AdCom meeting Sept 7, 2022; PDUFA decision date Sept 29, 2022 for ALS NDA.","EU MAA under review; decision expected first half 2023; commercial prep underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218745","json":"https://secwatch.observer/filing/0001193125-22-218745.json","markdown":"https://secwatch.observer/filing/0001193125-22-218745.md","text":"https://secwatch.observer/filing/0001193125-22-218745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312522218745/0001193125-22-218745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312522218745/d392710d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:54:03.083225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}